Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland

References

• Silveira C, Marques-Teixeira J, de Bastos-Leite AJ. More than one century of schizophrenia: an evolving perspective. J Nerv Ment Dis 2012;200:1054-7
   PubMed Web of Science ®Google Scholar
• Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279-93
   PubMed Web of Science ®Google Scholar
• Hansson L. Determinants of quality of life in people with severe mental illness. Acta Psychiatr Scand 2006;113(429 Suppl):46-50
   Web of Science ®Google Scholar
• Foldemo A, Gullberg M, Ek A-C, et al. Quality of life and burden in parents of outpatients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2005;40:133-8
   PubMed Web of Science ®Google Scholar
• Lafeuille MH, Gravel J, Lefebvre P, et al. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ 2013;16:1290-9
   PubMedGoogle Scholar
• Daltio CS, Mari JJ, Ferraz MB. Direct medical costs associated with schizophrenia relapses in health care services in the city of São Paulo. Rev Saude Publica 2011;45:14-23
   PubMed Web of Science ®Google Scholar
• Hong J, Windmeijer F, Novick D, et al. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:835-41
   PubMed Web of Science ®Google Scholar
• Higashi K, Medic G, Littlewood KJ, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of non-adherence, a systematic literature review. Ther Adv Psychopharmacol 2013;3:200-18
   PubMedGoogle Scholar
• Olivares JM, Sermon J, Hemels M, et al. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry 2013;12:32
   PubMed Web of Science ®Google Scholar
• Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence 2013;7:1171-80
   PubMed Web of Science ®Google Scholar
• Bera R, Offord S, Zubek D, et al. Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. J Med Econ 2013;16:522-8
   PubMedGoogle Scholar
• Abilify Maintena, aripiprazole Summary of product characteristics. London, UK: European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002755/human_med_001711.jsp&mid=WC0b01ac058001d124. Accessed May 3, 2015
   Google Scholar
• Zypadhera, olanzapine Summary of product characteristics. London, UK: European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000890/human_med_001188.jsp&mid=WC0b01ac058001d124. Accessed May 3, 2015
   Google Scholar
• Xeplion, paliperidone Summary of product characteristics. London, UK: European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002105/human_med_001424.jsp&mid=WC0b01ac058001d124. Accessed May 3, 2015
   Google Scholar
• Risperdal Consta (risperidone) Summary of product characteristics. London, UK: European Medicines Agency, 2007. London, UK: European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Risperdal_Consta_30/WC500008168.pdf. Accessed May 3, 2015
   Google Scholar
• Einarson TR, Pudas H, Zilbershtein R, et al. Pharmacoeconomic analysis of atypical antipsychotic depots for chronic schizophrenia in Finland. J Med Econ 2013;16:1096-105
   PubMedGoogle Scholar
• Ministry of Social Affairs and Health, Finland. Guidelines for preparing a health economic evaluation. http://www.ispor.org/PEguidelines/source/GuidelinesinFinland_EnglishVersion.pdf. Helsinki, Finland, 2009. Accessed April 26, 2015
   Google Scholar
• National Collaborating Centre for Mental Health. Schizophrenia: The NICE guidelines on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Updated edition. National Clinical Guideline Number 82. London, UK: National Institute for Health and Clinical Excellence, 2010.
   Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schiz Res 2004;71:155-75
   PubMed Web of Science ®Google Scholar
• Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 1996;11:101-8
   PubMed Web of Science ®Google Scholar
• Abilify Maintena® summary of product characteristics. London, UK: European Medicines Agency, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002755/WC500156111.pdf. Accessed May 3, 2015
   Google Scholar
• Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. J Clin Psychiatry 2014;75:1254-60
   PubMed Web of Science ®Google Scholar
• Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 2009;70:572-81
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Zypadhera Summary of product characteristics. London, UK: European Medicines Agency, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000890/WC500054429.pdf. Accessed May 5, 2015
   Google Scholar
• Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69:790-9
   PubMed Web of Science ®Google Scholar
• Xeplion Summary of product characteristics. London, UK: European Medicines Agency, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002105/WC500103317.pdf. Accessed May 6, 2015
   Google Scholar
• Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010;116:107-17
   PubMed Web of Science ®Google Scholar
• Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010;25:247-56
   PubMed Web of Science ®Google Scholar
• Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010;13:635-47
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010;35:2072-82
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Lindenmayer J-P, Lull JM, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010;30:235-44
   PubMed Web of Science ®Google Scholar
• Takahashi N, Takahashi M, Saito T, et al. Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia. Neuropsychiatr Dis Treat 2013;8:1889-98
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Risperdal Consta_ summary of product characteristics. London, UK, 2008. characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Risperdal_Consta_30/WC500008170.pdf. Accessed May 5, 2015
   Google Scholar
• Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, Simpson G. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218-26
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Lindenmayer JP, Kwentus J, et al. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. Schizophr Res 2014;154:14-22
   PubMed Web of Science ®Google Scholar
• Fu DJ, Bossie CA, Sliwa JK, et al. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. Int Clin Psychopharmacol 2014;29:45-55
   PubMed Web of Science ®Google Scholar
• Li H, Rui Q, Ning X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1002-8
   PubMed Web of Science ®Google Scholar
• Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008;6:105
   PubMed Web of Science ®Google Scholar
• Cummins C, Stevens A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia. A West Midlands Development and Evaluation Committee Report. Birmingham, UK: Department of Public Health & Epidemiology, University of Birmingham, 1998
   Google Scholar
• Hough D, Lindenmayer J-P, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1022-31
   PubMed Web of Science ®Google Scholar
• Oh PI, Lanctôt KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ 2001;4:137-56
   Google Scholar
• Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:617-24
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries D, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453-60
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Daniel DG, Carson WH, et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007;41:895-905
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-71
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW1, Sanchez R, Johnson B, et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol 2013;28:171-6
   PubMed Web of Science ®Google Scholar
• Detke HC, Lauriello J, Landry J, McDonnell DP. Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatment. Int J Methods Psychiatr Res 2014;23:439-50
   PubMed Web of Science ®Google Scholar
• Kane J, Detke H, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167:181-9
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Peng X, Montgomery W, et al. Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia. Eur Psychiatry 2011;26:313-19
   PubMed Web of Science ®Google Scholar
• Asseburg C, Willis M, Löthgren M, et al. Hospitalisation utilisation and costs in schizophrenia patients in Finland before and after initiation of risperidone long-acting injection. Schizophr Res Treatment 2012;2012:791468
   PubMedGoogle Scholar
• Mehnert A, Diels J. Impact of administration interval on treatment retention with long-acting antipsychotics in schizophrenia. Presented at the Tenth Workshop on Costs and Assessment in Psychiatry -Mental Health Policy and Economics; Venice, Italy, 25-27 March 2011
   Google Scholar
• Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2010;25:685-97
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 2012;15:107-18
   PubMed Web of Science ®Google Scholar
• Olivares J, Peuskens J, Pecanek J, et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009;25:2197-206
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Montgomery WS, McDonnell DP, et al. Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. Int J Gen Med 2012;5:391-8
   PubMedGoogle Scholar
• Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone - analysis of long-term efficacy. J Psychopharmacol 2005;19:15-21
   PubMed Web of Science ®Google Scholar
• Lee M, Ko Y, Lee S, et al. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Hum Psychopharmacol 2006;21:399-407
   PubMed Web of Science ®Google Scholar
• Lindenmayer J-P, Khan A, Eerdekens M, et al. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2007;17:138-44
   PubMed Web of Science ®Google Scholar
• Möller H-J, Llorca P-M, Sacchetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005;20:121-30
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodrigues-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
   PubMed Web of Science ®Google Scholar
• IMS Health Oy SLD price. Finland: Suomen LääkeData Oy. http://www.sld.fi/finland.html. Accessed April 22, 2014
   Google Scholar
• Price list: Kliinisen Kemian Laboratoriotutkimusten Ja Verivalmisteiden. Hinnasto 2015. Seinäjoki, Finland: Etelä-Pohjanmaan sairaanhoitopiiri, January 1, 2015
   Google Scholar
• Kapiainen S, Väisänen A, Haula T. Terveyden- ja sosiaalihuolloin yksikkökustannukset Suomessa vuonna 2011. Raportti 3/2014. Terveyden ja hyvinvoinnin laitos. https://www.julkari.fi/bitstream/handle/10024/114683/THL_RAPO3_2014_web.pdf?sequence=1. Tampere, Finland 2014. Accessed May 3, 2015
   Google Scholar
• HUS Palveluhinnasto 2014. Osa 2 Suoriteperusteiset sairaanhoidolliset palvelut. http://www.hus.fi/hus-tietoa/talous/Hinnoittelu/Documents/HUS%20Palveluhinnasto%202014%20OSA%202.pdf. Helsinki, Finland 2014 Accessed May 3, 2015
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Triami Media BV. Inflation.eu website. http://www.inflation.eu/inflation-rates/finland/historic-inflation/cpi-inflation-finland-2015.aspx. Accessed May 3, 2015
   Google Scholar
• European Central Bank. Euro foreign exchange reference rates. Frankfurt-am-Main, Germany, 2015. https://www.ecb.europa.eu/stats/exchange/eurofxref/html/eurofxref-graph-gbp.en.html. Accessed July 14, 2015
   Google Scholar
• Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin 2008;24:3341-55
   PubMed Web of Science ®Google Scholar
• Carroll SM, Jemiai N, Suter B, et al. Cost-effectiveness analysis of olanzapine long-acting injection compared with risperidone long-acting injection in the treatment of schizophrenia in Norway. Abstract PMH42. Value Health 2009;12:A358
   Google Scholar
• Hensen M, Heeg B, Löthgren M, et al. Cost effectiveness of long-acting risperidone in Sweden. Appl Health Econ Health Policy 2010;8:327-41
   PubMedGoogle Scholar
• Heeg B, Buskens E, Botteman M, et al. The cost-effectiveness of atypicals in the UK. Value Health 2008;11:1007-21
   PubMed Web of Science ®Google Scholar
• Heeg BM, Antunes J, Figueira ML, et al. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise. Curr Med Res Opin 2008;24:349-58
   PubMed Web of Science ®Google Scholar
• Laux G, Heeg B, van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005;23(1 Suppl):49-61
   PubMed Web of Science ®Google Scholar
• Edgell ET, Andersen SW, Johnstone BM, et al. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000;18:567-79
   PubMed Web of Science ®Google Scholar
• Einarson TR, Zilbershtein R, Skoupá J, et al. Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. J Med Econ 2013;16:1089-95
   PubMedGoogle Scholar
• Einarson TR, Geitona M, Chaidemenos A, et al. Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. Ann Gen Psychiatry 2012;11:18
   PubMed Web of Science ®Google Scholar
• Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. Acta Neuropsychiatr 2013;25:85-94
   PubMed Web of Science ®Google Scholar
• Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nord J Psychiatry 2014;68:416-27
   PubMed Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin 2011;27:713-30
   PubMed Web of Science ®Google Scholar
• Hemels MEH, Einarson TR, Zilbershtein R, et al. Cost-effectiveness of injectable atypical long-acting antipsychotics for chronic schizophrenia in Poland. J Health Policy Outcomes Res 2013;2:50-55
   PubMed Web of Science ®Google Scholar
• Jukic V, Jakovljevic M, Filipcic I, et al. Cost-utility analysis of depot antipsychotics for chronic schizophrenia in Croatia. Value Health Reg J Cent East Eur 2013;2:181-8
   Google Scholar
• Mehnert A, Nicholl D, Pudas H, et al. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J Med Econ 2012;15:844-61
   PubMedGoogle Scholar
• Zeidler J, Mahlich J, Greiner W, et al. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany. Appl Health Econ Health Policy 2013;11:509-21
   PubMedGoogle Scholar
• Citrome L, Kamat SA, Sapin C, et al. Cost effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. J Med Econ 2014;17:567-76
   PubMedGoogle Scholar
• Pigott TA, Carson WH, Saha AR; Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-56
   PubMed Web of Science ®Google Scholar
• Lindström E, Eberhard J, Fors BM, et al. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nord J Psychiatry 2011;65:403-13
   PubMed Web of Science ®Google Scholar
• Obradovic M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract 2007;61:1979-88
   PubMed Web of Science ®Google Scholar
• Geitona M, Kousoulakou H, Ollandezos M, et al. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry 2008;7:16
   PubMedGoogle Scholar
• Park T, Kuntz KM. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia. Value Health 2014;17:310-19
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 2009;65:510-17
   PubMed Web of Science ®Google Scholar
• Hsieh MH, Lin WW, Chen ST, et al. A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting. Ann Gen Psychiatry 2010;9:35
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37
   PubMed Web of Science ®Google Scholar